Echoiq Limited · ASX:EIQ
Echoiq — Conference Presentation (November 2025)
20 slides from Echoiq's conference presentation, November 2025
Slide 1: Webinar Presentation
Webinar Presentation November 2025 ASX: EIQ OTC: ECHQF 1
Slide 2: Disclaimer and Forward-looking Statements
Disclaimer and Forward-looking Statements This presentation has been prepared by ECHOIQ LIMITED “EIQ”. This document contains jurisdiction of the United States, and may not be offered or sold in the United States to background information about EIQ current at the date of this presentation. The any p
Slide 3: EchoSolv AI processing
EchoSolv™ Al processing +LVOT Diam | LVOT Area 3.14 c
Slide 4: EchoSolv AI processing
EchoSolv AI processing CON FIDENTIAL 4
Slide 5: A major US market opportunity: US$65B and growing
A major US market opportunity: US$65B and growing $87B Heart Failure $70B The US Healthcare expenditure $55B Heart Failure CAGR Market Size 4.5% 2025 2026 2030 2031 2035 Aortic Stenosis The US Healthcare expenditure Aortic Stenosis CAGR $24B $16B Market $10B Size 8.1% 2025 2026 2030 2031 2035
Slide 6: Aortic Stenosis is the most common valvular heart disease in adults over 75
Aortic Stenosis is the most common valvular heart disease in adults over 75 Aortic stenosis 1 in 2 760K 2 years people with heart valve American adults over 65 50% mortality rate for untreated disease don’t know they symptomatic severe aortic stenosis impacted by Aortic Stenosis have it (sAS) 11.5 h
Slide 7: Heart Failure is a significantly larger issue
Heart Failure is a significantly larger issue 6.5M 1M 25% Adults (>20 years) in the US New heart failure cases of Medicare patients with HF are who have heart failure Per annum readmitted within 30 days 5.2 hospital days US$24K 5 years Average per-patient annual cost of 50% of people with HF die Mea
Slide 8: Commercial Pathway
Commercial Pathway Three critical stages to accelerate revenue growth into 2026 Hospital Integrations Integrated Free trial for all customers Reimbursement & Revenue Accelerated Sales CY26 • [Converts to subscription model at conclusion] Subscription Model 3 Distinct targets: • Subscription solution
Slide 9: Subscription Model
Subscription Model Subscription Model Graduated model based on reimbursement approval rates Mechanisms ✓ Removes reimbursement approval rate approval risk Sites range from 5,000 → 200,000 p.a $150-$299 / Claim ✓ Fast-tracks sales cycle ✓ Maintains market value Annual Number of Average ✓ Incentivises
Slide 10: EchoSolv HF: The potential solution
EchoSolv HF: The potential solution Study Outputs: 50% of patients in this cohort were misdiagnosed or underdiagnosed AI alone detected 86% of patients with i g HF AI with Cardiologist review detected CL INICA L cas PRAC TIC E es usi 97% of patients with HF 10 Disclaimer: EchoSolv HF is not FDA or T
Slide 11: Validation Results
Validation Results The clinical validation was designed to evaluate the EchoSolv HF model’s ability to detect heart failure on an independent dataset of ~17,000 individual echo studies. Sensitivity: Specificity: Identifying patients accurately with Heart Failure Identifying patients accurately witho
Slide 12: Near term regulatory pathway
Near term regulatory pathway Completion of the clinical validation marks the final clinical requirement prior to a formal submission for clearance by the US FDA EIQ will shortly complete its formal submission to advance the clearance of EchoSolv HF via the FDA’s 510(k) regulatory pathway with submis
Slide 13: Accelerating innovation through exclusive data access
Accelerating innovation through exclusive data access Mitral Valve Regurgitation Development 2028 Pulmonary Hypertension Development Hypertrophic Cardiomyopathy Heart Development 2026 Failure FDA Aortic Submission Stenosis Q4 CY25 FDA 510(k) Cleared Disclaimer: EchoSolv HF, HCM, PH, or MR are not FD
Slide 14: Upcoming presentations
Upcoming presentations: Consider removing depending on final length • Piper Sandler Healthcare Conference Dec 2-3 • JP Morgan Healthcare Conference Jan 12-15
Slide 15: Head of Commercial
Head of Commercial Nick Lubbers
Slide 16: Background
BACKGROUND • New market creation, Left Atrial • New market creation, Fractional • New market creation, predictive Appendage Closure (LAAC) Flow Reserve via CT (FFRct) ECG algorithm for AF, AS and PAH. • Established CMS Nation Coverage • Established CMS Local Coverage • Initial FDA clearance for ECG-
Slide 17: Opportunity
OPPORTUNITY Real world Seamless Reimbursement evidence integration into pathway existing clinical workflows Trained on >2M EchoSolv results are CMS has recognised echocardiogram delivered within the hospital outpatient, measurements existing PACS and inpatient and linked to mortality Reporting platf
Slide 18: Echo AI Landscape
ECHO AI LANDSCAPE EchoSolv Adjacent Technologies Competitive Landscape COMPETITION IMAGE DEPENDENT AI ACQUISITION AI SCREENING AI AI trained on >2M Image dependent echocardiogram Impacted by measurements Heart Failure image quality Measurement algorithm specific ECG-AI and Access to DICOM performanc
Slide 19: Advancing a defined commercial strategy
Advancing a defined commercial strategy Top 250 200% • Active outreach to the Top 250 • 200% increase in customer • EchoSolv AS creates an FDA healthcare sites by adjudicated engagement for EchoSolv AS cleared point of entry to deliver echocardiography volume. across: upon an echocardiography • oper
Slide 20: Q&A
EchoSo!lv Q&A